摘要
目的观察芪参二莲汤联合恩替卡韦治疗慢性乙型病毒性肝炎的临床疗效。方法将62例慢性乙型病毒性肝炎患者随机分为治疗组(32例)和对照组(30例)。对照组予恩替卡韦片,治疗组在对照组治疗措施基础上加服芪参二莲汤。两组疗程均为1年,随访6个月。观察病毒应答(早期EVR、结束时ETVVR、持续SVR)疗效,比较e抗原转阴率、肝功能(ALT、AST、TBIL)及血清IL-4、IFN-γ水平的变化情况。结果 1治疗组、对照组EVR分别为68.75%、33.33%,差异有统计学意义(P<0.05);ETVR分别为78.13%、50.00%,两组差异有统计学意义(P<0.05);SVR分别为71.88%、36.67%,两组差异有统计学意义(P<0.05)。2治疗后两组比较,e抗原转阴率差异有统计学意义(P<0.05);随访至6个月时两组比较,e抗原转阴率差异有统计学意义(P<0.05)。3治疗前后组内比较,两组AST、ALT、TBIL水平差异有统计学意义(P<0.05);组间治疗后比较,AST、ALT、TBIL水平差异无统计学意义(P>0.05)。4治疗前后组内比较,两组IL-4、IFN-γ水平差异有统计学意义(P<0.05);组间治疗后比较,IL-4、IFN-γ水平差异有统计学意义(P<0.05);组间随访至6个月时比较,IL-4、IFN-γ水平差异有统计学意义(P<0.05)。结论芪参二莲汤联合恩替卡韦治疗慢性乙型病毒性肝炎,可显著抑制HBV-DNA的复制,同时可通过调节IFN-γ与IL-4的平衡,提高机体免疫力。
Objective To observe the clinical efficacy of ＂Qishen Erlian Decoction＂ combined with Entecavir on patients with chronic hepatitis B. Methods 62 patients with chronic hepatitis B were randomly divided into control group （30 cases） and treatment group （32 cases ）, in which the control group received Entecavir tablets while the treatment group received ＂Qishen Erlian Decoction＂ on the basis of Entecavir tablets. Two groups of patients with a course of 1 year and were followed up for 6 Months. We observed the virological responses, e antigen conversion rates, liver function （ ALT, AST, TBIL） and IL4, IFN-γ,levels. Results （1）The EVR of the two groups was 68.75% and 33.33% , ETVR was 78. 13% and 50% , SVR was 71.88% and 36.67% , the difference was statistically significant （ P 〈 0. 05 ） ; （2）Compared between the two groups after the treatment and 6 months follow-up, difference was statistically significant on the e antigen conversion rate （ P 〈 0.05 ） ; （3） Comparison with pre-treatment, difference were statistically significant in AST, ALT, TBIL levels of both groups （ P 〈 0.05 ）, between the two groups after treatment, AST, ALT, TBIL levels had no significant difference （ P 〉 0.05 ） ; （4） Comparison with pre-treatment, difference were statistically significant in IL-4, IFN-γ levels of both groups （P 〈 0.05 ）, between the two groups after the treatment, IL-4, IFN-γ levels were significantly （ P 〈 0.05 ） ; between the two groups at follow-up to 6 months, IL-4, IFN-γ levels were significantly （P 〈 0.05 ）. Conclusion The clinical effect of ＂Qishen Erlian Decoction＂ combined with Entecaviris on patients with chronic hepatitis B was significant, not only can significantly inhibit the replication of HBV-DNA, but also regulate IL4 and IFN-γ, levels, thereby enhancing the body~ ability to clear the virus, promoting e antigen conversion.
出处
《上海中医药杂志》
2015年第12期35-38,共4页
Shanghai Journal of Traditional Chinese Medicine
